TY - JOUR
T1 - Comparison of therapeutic lipid target achievements among high-risk patients in Oman
AU - Al-Waili, Khalid
AU - Al-Zakwani, Ibrahim
AU - Al-Dughaishi, Tamima
AU - Baneerje, Yajnavalka
AU - Al-Sabti, Hilal
AU - Al-Hashmi, Khamis
AU - Farhan, Hatem
AU - Habsi, Khadija Al
AU - Al-Hinai, Ali T.
AU - Al-Rasadi, Khalid
PY - 2014/5
Y1 - 2014/5
N2 - We compared therapeutic lipid target achievements among patients with diabetes or coronary heart disease (CHD) in Oman. A retrospective chart review of 94 patients was conducted at an outpatient clinic in Sultan Qaboos University Hospital, Muscat, Oman. The variables included low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and apolipoprotein B (apo B). The overall mean age of the cohort was 59 ± 12 years, 54% were male, 66% were diabetic, 48% hypertensive, 45% had CHD, 94% were on simvastatin, 4% were on fenofibrate, and 2% were on both simvastatin and fenofibrate. Lipid goal attainments of calculated LDL-C (<2.6 mmol/L), apo B (<0.9 g/L), and non-HDL-C (<3.36 mmol/L) were reached in 52%, 39%, and 53% of the patients, respectively. A significant proportion of high-risk patients treated with lipid-lowering agents reach LDL-C but not the apo B treatment targets, suggesting that the use of apo B target values should also be considered.
AB - We compared therapeutic lipid target achievements among patients with diabetes or coronary heart disease (CHD) in Oman. A retrospective chart review of 94 patients was conducted at an outpatient clinic in Sultan Qaboos University Hospital, Muscat, Oman. The variables included low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and apolipoprotein B (apo B). The overall mean age of the cohort was 59 ± 12 years, 54% were male, 66% were diabetic, 48% hypertensive, 45% had CHD, 94% were on simvastatin, 4% were on fenofibrate, and 2% were on both simvastatin and fenofibrate. Lipid goal attainments of calculated LDL-C (<2.6 mmol/L), apo B (<0.9 g/L), and non-HDL-C (<3.36 mmol/L) were reached in 52%, 39%, and 53% of the patients, respectively. A significant proportion of high-risk patients treated with lipid-lowering agents reach LDL-C but not the apo B treatment targets, suggesting that the use of apo B target values should also be considered.
KW - Oman
KW - apolipoprotein B
KW - coronary heart disease
KW - diabetes mellitus
KW - low-density lipoprotein cholesterol
UR - http://www.scopus.com/inward/record.url?scp=84898954962&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84898954962&partnerID=8YFLogxK
U2 - 10.1177/0003319713482572
DO - 10.1177/0003319713482572
M3 - Article
C2 - 23564019
AN - SCOPUS:84898954962
SN - 0003-3197
VL - 65
SP - 430
EP - 435
JO - Angiology
JF - Angiology
IS - 5
ER -
